Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How Fusion Antibodies fits into the life sciences cohort of the FTSE AIM All Share Index

Fusion Antibodies is a contract services organisation focused on therapeutic and diagnostic antibodies. It provides services to pharmaceutical and biotechnology customers across the drug discovery and early development process, including antibody discovery, sequencing, engineering and humanisation, and the supply of laboratory-grade material. Humanisation, which …

Divya Sood | 19 October 2026

What investors should know about Faron Pharmaceuticals as a FTSE AIM All Share Index biotech

Faron is based in Turku, Finland, and is listed both on AIM in London and on Nasdaq First North Growth Market in Helsinki. It describes itself as a clinical-stage biopharmaceutical company focused on tackling cancer through novel immunotherapies. Its lead programme is bexmarilimab, an …

Divya Sood | 19 October 2026

What Feedback Is Waiting For as a FTSE AIM All Share Index Health-Tech Small Cap

Feedback develops Bleepa, a clinical communications and medical imaging platform designed to help NHS clinicians share information and manage patient pathways outside traditional outpatient settings. Bleepa accounted for roughly 89% of sales in a recent reporting period. The company's strategy centres on community diagnostic …

Divya Sood | 19 October 2026

How an Arnold Clark screening deal reshapes EDX Medical Group on the FTSE AIM All Share Index

EDX Medical develops and supplies digital diagnostic products and services aimed at the early detection and treatment of major diseases. Its offering includes biomarker testing panels, prostate cancer testing and an employee health screening service that combines blood tests with general health and family …

Divya Sood | 19 October 2026

What EKF Diagnostics Half-Year Margins Signal for Its Place in the FTSE AIM All Share Index

Headquartered in Cardiff, EKF Diagnostics develops, manufactures and sells diagnostic products. Its business is split into two divisions. Point-of-Care covers analysers and consumables for haemoglobin testing, including the DiaSpect and HemoPoint ranges, and diabetes testing. Life Sciences includes the company's beta-hydroxybutyrate (β-HB) reagent business, …

Divya Sood | 19 October 2026

Why Cambridge Nutritional Sciences (LSE:CNSL) Is a Focused Diagnostics Name in the FTSE AIM All Share Index

Cambridge Nutritional Sciences develops and manufactures in vitro diagnostic tests, with a focus on food intolerance and nutrition-related testing. Its products are designed to help practitioners and individuals identify foods that may be associated with adverse reactions, and are sold through laboratories, clinics, nutritional …

Ankur Sharma | 19 October 2026

Why Cambridge Cognition (LSE:COG) Is Widening Its Reach Beyond Drug Trials Within the FTSE AIM All Share Index

Cambridge Cognition develops digital tools for assessing cognitive function. Its best-known product, CANTAB, is a suite of computerised tests used in academic studies and by pharmaceutical companies running clinical trials in areas such as neurology and psychiatry. The company also provides electronic clinical outcome …

Ankur Sharma | 19 October 2026

How Coiled Therapeutics (LSE:COIL) Fits into the FTSE AIM All Share Index

Coiled Therapeutics is a therapeutics-focused company quoted on AIM. Businesses in this field typically work on a technology platform or a pipeline of drug candidates aimed at specific diseases, advancing them through preclinical work and clinical trials before seeking regulatory approval or a partner …

Ankur Sharma | 19 October 2026

CelLBxHealth (LSE:CLBX) and its place on the FTSE AIM All Share Index

CelLBxHealth operates in the life sciences field, where companies typically develop technologies and products aimed at clinical and laboratory users. When an AIM company changes its name, it is often signalling a new strategic direction, a refreshed brand for an existing product, or a …

Ankur Sharma | 19 October 2026

What Arecor Therapeutics (LSE:AREC)' Fundraising Means for Its FTSE AIM All Share Index Insulin Story

Arecor develops therapeutics for diabetes, obesity and other cardiometabolic diseases. Its main focus is two insulin candidates: AT278, an ultra-concentrated, ultra-rapid-acting insulin at 500 units per millilitre, and AT290, at 200 units per millilitre. The company believes concentrated insulins could enable longer-wear, smaller and …

Ankur Sharma | 19 October 2026
Support

Hi! How can we help you today?

Loading…